12.6
クロスオーバー実験は、反復測定デザインとも呼ばれ、すべての実験ユニットが異なる期間にすべての処理にさらされる研究デザインです。クロスオーバー実験は通常、心理学、製薬産業、農業、医学で使用されます。
サンプルはコントロールとして機能するため、サンプル サイズが小さくてもクロスオーバー デザインが実行さ…
クロスオーバースタディデザインは、反復測定デザインとも呼ばれ、実験ユニットが異なる期間のすべての治療を受けます。
たとえば、10人の喘息患者をグループ1とグループ2に無作為に分けて、薬剤Aと薬剤Bを比較する臨床試験を考えてみましょう。
まず、各グループごとに異なる薬を2週間投与し、患者の生理機能への影響を記録します。これに続いて、患者の体から薬物を排除するためのウォッシュアウト期間が続きます。
ここで、2 番目のグループが薬剤 A を受け取り、最初のグループが薬剤 B を受け取るように、グループが切り替えられます。これはクロスオーバー設計と呼ばれます。このデザインでは、被験者は独自のコントロールとして機能し、被験者の特性は研究全体で変更されません。また、主題間のばらつきも取り除きます。
このデザインは、一般的に、症状を完全に治すのではなく、症状をコントロールするのに役立つ薬剤を含む後期臨床試験で使用されます。
例えば、前の例では、薬剤 A が最初の期間に患者を治癒した場合、薬剤 B はその有効性を実証する機会がありません。
View the full transcript and gain access to JoVE Core videos
Q1: What is a crossover experiment and how does it differ from other study designs?
A crossover experiment, also called a repeated measurements design, exposes all experimental units to every treatment across different time periods. Unlike simple randomized trials, subjects act as their own controls, eliminating inter-subject variability. This approach is particularly valuable in clinical trials where patients receive all treatments sequentially, with washout periods between exposures to clear previous treatments from the body.
Q2: Why is a washout period necessary in crossover studies?
A washout period eliminates residual effects of the previous treatment from the subject's body before introducing the next treatment. This prevents carryover effects that could confound results and compromise data validity. Without adequate washout time, the lingering effects of one drug could artificially influence responses to the subsequent treatment, making it impossible to isolate each treatment's true effect.
Q3: When are crossover designs most appropriate in pharmaceutical research?
Crossover designs are ideal for late-phase clinical trials testing drugs that control symptoms rather than cure diseases completely. They work well for comparing bioavailability or drug ingestion in the human body against reference drugs. However, crossover designs are unsuitable for chronic, stable diseases or when drugs provide complete cures, as treatment effects would prevent meaningful comparison of subsequent treatments.
Q4: How do subjects serve as their own controls in crossover experiments?
In crossover designs, each subject receives all treatments sequentially, allowing researchers to compare treatment effects within the same individual. Since subjects' characteristics remain constant throughout the study, differences in outcomes directly reflect treatment effects rather than individual variation. This internal comparison eliminates confounding variables associated with inter-subject differences, making crossover designs more statistically powerful than between-subject comparisons.
Q5: What are the advantages of using crossover designs with smaller sample sizes?
Crossover designs require smaller sample sizes than simple randomized trials because each subject provides data for all treatment conditions. Since subjects act as their own controls, researchers can detect treatment differences more efficiently with fewer participants. This efficiency makes crossover designs cost-effective and practical in fields like psychology, pharmaceuticals, agriculture, and medicine where sample recruitment may be limited.
Q6: What is an example of how crossover experiments work in clinical drug trials?
In a typical example, asthmatic patients are randomly divided into two groups. Group one receives drug A for two weeks while group two receives drug B, with effects recorded. After a washout period, the groups switch treatments. This design allows researchers to compare both drugs' effectiveness within the same patients, ensuring fair comparison while controlling for individual patient characteristics that might influence drug response.
Q7: Why are crossover designs unsuitable for studying chronic diseases?
Crossover designs fail for chronic, stable diseases because if the first treatment cures or substantially improves the condition, the disease may not return during the washout period. This prevents meaningful evaluation of subsequent treatments. For example, if drug A cures asthma in the first period, drug B cannot demonstrate its effectiveness in the second period, making treatment comparison impossible and invalidating the study's conclusions.